Skip to main content

  • All resources
  • LGS
  • TSC
  • Dravet
  • Prescribing and Using EPIDIOLEX
  • Treatment Partnership
  • Patient Cases
  • REST-LGS

DES Eyebrow

  • Prescribing Information
  • EPIDIOLEXhcp.com
  • EPIDIOLEX Experience

Results

Video of Dr. Danielle Becker
9:24

Diagnosing an Adult Patient With TSC

with Dr. Danielle Becker

Diagnosing an Adult Patient With TSC

with Dr. Danielle Becker

A case study of a hypothetical patient with TSC who has been transferred to your care.

Suggested chapters:

  • 0:00—1:49 Introduction
  • 1:49—3:10 Patient Case: Trevor
  • 3:10—8:34 Diagnosis: TSC
  • 8:34—9:24 After the Diagnosis
Video of Dr. Jesus Eric Piña-Garza
18:22

Finding Answers for Patients With Epilepsy Syndromes

with Dr. Jesus Eric Piña-Garza

Finding Answers for Patients With Epilepsy Syndromes

with Dr. Jesus Eric Piña-Garza

Dr. Piña-Garza explains the signs and symptoms related to tuberous sclerosis complex (TSC), Lennox-Gastaut syndrome (LGS), and Dravet syndrome.

Suggested chapters:

  • 0:00—1:30 Introduction
  • 1:30—5:47 Diagnosing Tuberous Sclerosis Complex (TSC)
  • 5:47—8:15 Diagnosing Lennox-Gastaut Syndrome (LGS) and Dravet Syndrome
  • 8:15—13:40 Diagnosing LGS
  • 13:40—17:31 Diagnosing Dravet Syndrome
  • 17:31—18:22 Reach Out to Your Local NAM for Further Information

Explore featured content

Videos
Video of Dr. Selim Benbadis
28:06

A Potential Treatment Partnership for LGS

with Dr. Selim Benbadis

A Potential Treatment Partnership for LGS

with Dr. Selim Benbadis

Dr. Benbadis discusses how EPIDIOLEX and another established ASM work together to potentially reduce seizures in LGS.

Video of Dr. Danielle Becker
19:04

Diagnosing Adult Patients With Epilepsy Syndromes

with Dr. Danielle Becker

Diagnosing Adult Patients With Epilepsy Syndromes

with Dr. Danielle Becker

Dr. Becker highlights how to evaluate and accurately diagnose an adult patient with LGS, Dravet syndrome, or TSC.

Understanding Access and Affordability of EPIDIOLEX video
19:16

Understanding Access and Affordability of EPIDIOLEX

with Karen Keough, MD, and Amber Steele, RN

Understanding Access and Affordability of EPIDIOLEX

with Karen Keough, MD, and Amber Steele, RN

Dr. Keough and Amber Steele discuss access to and affordability of EPIDIOLEX to help your patients get started on treatment.

Important Safety Information & Indications

Contraindication: Hypersensitivity

EPIDIOLEX (cannabidiol) oral solution is contraindicated in patients with a history of hypersensitivity to cannabidiol or any ingredients in the product.

Warnings & Precautions

Hepatic Injury:

EPIDIOLEX can cause dose-related transaminase elevations. Concomitant use of valproate and elevated transaminase levels at baseline increase this risk. Obtain transaminase and bilirubin levels prior to starting treatment, at 1, 3, and 6 months after initiation of treatment, and periodically thereafter, or as clinically indicated. Resolution of transaminase elevations occurred with discontinuation of EPIDIOLEX, reduction of EPIDIOLEX and/or concomitant valproate, or without dose reduction. For patients with elevated transaminase levels, consider dose reduction or discontinuation of EPIDIOLEX or concomitant medications known to affect the liver (e.g., valproate or clobazam). Dose adjustment and slower dose titration is recommended in patients with moderate or severe hepatic impairment. Consider not initiating EPIDIOLEX in patients with evidence of significant liver injury. There have been postmarketing reports of cholestatic or mixed patterns of liver injury. Elevated ammonia levels were reported in some patients with transaminase elevations; most taking concomitant valproate, clobazam, or both. Consider discontinuation or dose adjustment of valproate or clobazam if ammonia is elevated.

Somnolence and Sedation:

EPIDIOLEX can cause somnolence and sedation that generally occurs early in treatment and may diminish over time; these effects occur more commonly in patients using clobazam and may be potentiated by other CNS depressants.

Suicidal Behavior and Ideation:

Antiepileptic drugs (AEDs), including EPIDIOLEX, increase the risk of suicidal thoughts or behavior. Inform patients, caregivers, and families of the risk and advise them to monitor and report any signs of depression, suicidal thoughts or behavior, or unusual changes in mood or behavior. If these symptoms occur, consider if they are related to the AED or the underlying illness.

Withdrawal of Antiepileptic Drugs:

As with most AEDs, EPIDIOLEX should generally be withdrawn gradually because of the risk of increased seizure frequency and status epilepticus.

Adverse Reactions:

The most common adverse reactions in patients receiving EPIDIOLEX (≥10% and greater than placebo) include transaminase elevations; somnolence; decreased appetite; diarrhea; pyrexia; vomiting; fatigue, malaise, and asthenia; rash; insomnia, sleep disorder and poor-quality sleep; and infections. Hematologic abnormalities were also observed.

Pregnancy:

EPIDIOLEX should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Encourage women who are taking EPIDIOLEX during pregnancy to enroll in the EPIDIOLEX Pregnancy Surveillance Program and the North American Antiepileptic Drug (NAAED) Pregnancy Registry.

Drug Interactions:

Strong inducers of CYP3A4 and CYP2C19 may affect EPIDIOLEX exposure. EPIDIOLEX may affect exposure to CYP2C19 substrates (e.g., clobazam, diazepam, stiripentol), orally administered P-gp substrates, or other substrates (see full Prescribing Information). Consider dose reduction of orally administered everolimus, with appropriate therapeutic drug monitoring, when everolimus is combined with EPIDIOLEX. A lower starting dose of everolimus is recommended when added to EPIDIOLEX therapy. Concomitant use of EPIDIOLEX and valproate increases the incidence of liver enzyme elevations. Pneumonia was observed more frequently with concomitant use of EPIDIOLEX and clobazam. Dosage adjustment of EPIDIOLEX or other concomitant medications may be necessary.

INDICATIONS:

EPIDIOLEX (cannabidiol) oral solution is indicated for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC) in patients 1 year of age and older.

Please read the EPIDIOLEX full Prescribing Information for additional important information.

DES footer

  • Privacy Policy
  • Terms of Use
  • Sitemap
  • Unsubscribe
Jazz Pharmaceuticals Logo

©2025 Jazz Pharmaceuticals, Inc. All rights reserved. US-EPX-2400081 Rev0425

Important safety information & indications

Important safety information & indications

CONTRAINDICATION: HYPERSENSITIVITY EPIDIOLEX (cannabidiol) oral solution is contraindicated in patients with a history of hypersensitivity to cannabidiol or any ingredients in the product. WARNINGS & PRECAUTIONS Hepatic Injury: EPIDIOLEX can cause dose-related transaminase elevations. Concomitant use of valproate and elevated transaminase levels at baseline increase this risk. Obtain transaminase and bilirubin levels prior to starting treatment, at 1, 3, and 6 months after initiation of treatment, and periodically thereafter, or as clinically indicated. Resolution of transaminase elevations occurred with discontinuation of EPIDIOLEX, reduction of...

CONTRAINDICATION: HYPERSENSITIVITY EPIDIOLEX (cannabidiol) oral solution is contraindicated in patients with a history of hypersensitivity to cannabidiol or any ingredients in the product.

Important Safety Information & Indications

Contraindication: Hypersensitivity

EPIDIOLEX (cannabidiol) oral solution is contraindicated in patients with a history of hypersensitivity to cannabidiol or any ingredients in the product.

Warnings & Precautions

Hepatic Injury:

EPIDIOLEX can cause dose-related transaminase elevations. Concomitant use of valproate and elevated transaminase levels at baseline increase this risk. Obtain transaminase and bilirubin levels prior to starting treatment, at 1, 3, and 6 months after initiation of treatment, and periodically thereafter, or as clinically indicated. Resolution of transaminase elevations occurred with discontinuation of EPIDIOLEX, reduction of EPIDIOLEX and/or concomitant valproate, or without dose reduction. For patients with elevated transaminase levels, consider dose reduction or discontinuation of EPIDIOLEX or concomitant medications known to affect the liver (e.g., valproate or clobazam). Dose adjustment and slower dose titration is recommended in patients with moderate or severe hepatic impairment. Consider not initiating EPIDIOLEX in patients with evidence of significant liver injury. There have been postmarketing reports of cholestatic or mixed patterns of liver injury. Elevated ammonia levels were reported in some patients with transaminase elevations; most taking concomitant valproate, clobazam, or both. Consider discontinuation or dose adjustment of valproate or clobazam if ammonia is elevated.

Somnolence and Sedation:

EPIDIOLEX can cause somnolence and sedation that generally occurs early in treatment and may diminish over time; these effects occur more commonly in patients using clobazam and may be potentiated by other CNS depressants.

Suicidal Behavior and Ideation:

Antiepileptic drugs (AEDs), including EPIDIOLEX, increase the risk of suicidal thoughts or behavior. Inform patients, caregivers, and families of the risk and advise them to monitor and report any signs of depression, suicidal thoughts or behavior, or unusual changes in mood or behavior. If these symptoms occur, consider if they are related to the AED or the underlying illness.

Withdrawal of Antiepileptic Drugs:

As with most AEDs, EPIDIOLEX should generally be withdrawn gradually because of the risk of increased seizure frequency and status epilepticus.

Adverse Reactions:

The most common adverse reactions in patients receiving EPIDIOLEX (≥10% and greater than placebo) include transaminase elevations; somnolence; decreased appetite; diarrhea; pyrexia; vomiting; fatigue, malaise, and asthenia; rash; insomnia, sleep disorder and poor-quality sleep; and infections. Hematologic abnormalities were also observed.

Pregnancy:

EPIDIOLEX should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Encourage women who are taking EPIDIOLEX during pregnancy to enroll in the EPIDIOLEX Pregnancy Surveillance Program and the North American Antiepileptic Drug (NAAED) Pregnancy Registry.

Drug Interactions:

Strong inducers of CYP3A4 and CYP2C19 may affect EPIDIOLEX exposure. EPIDIOLEX may affect exposure to CYP2C19 substrates (e.g., clobazam, diazepam, stiripentol), orally administered P-gp substrates, or other substrates (see full Prescribing Information). Consider dose reduction of orally administered everolimus, with appropriate therapeutic drug monitoring, when everolimus is combined with EPIDIOLEX. A lower starting dose of everolimus is recommended when added to EPIDIOLEX therapy. Concomitant use of EPIDIOLEX and valproate increases the incidence of liver enzyme elevations. Pneumonia was observed more frequently with concomitant use of EPIDIOLEX and clobazam. Dosage adjustment of EPIDIOLEX or other concomitant medications may be necessary.

INDICATIONS:

EPIDIOLEX (cannabidiol) oral solution is indicated for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC) in patients 1 year of age and older.

Please read the EPIDIOLEX full Prescribing Information for additional important information.

You are
about
to leave EPIDIOLEXhcp.com.

Stay here Stay on Epidiolex HCP Site Let's go! Leave Epidiolex HCP Site

Jazz Pharmaceuticals is not responsible for content on external, third-party websites.

 

Please select your preferred language

English Spanish

 

EPIDIOLEX® (cannabidiol) is now approved for the treatment of TSC-associated seizures in patients 1 year of age and older, following a clinical study that showed significant reductions in TSC-associated seizures. Find out what this means for your patients and your practice.

Press Release Prescribing Information
Epidiolex Cannabidiol Logo

Thank you for your response!

You will be directed to a relevant page on EPIDIOLEXhcp.com about a topic of your interest in a few seconds.

5

seconds